相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term Prospective Population PK Study in GIST Patients-Letter
Etienne Chatelut et al.
CLINICAL CANCER RESEARCH (2013)
Integrating Clinical Pharmacology Concepts in Individualized Therapy With Tyrosine Kinase Inhibitors
C. D. Drenberg et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
Sabrina Angelini et al.
HAEMATOLOGICA (2013)
Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response
Anne M. Filppula et al.
DRUG METABOLISM AND DISPOSITION (2013)
Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates
A. M. Filppula et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
Karel Eechoute et al.
CLINICAL CANCER RESEARCH (2012)
Drug-Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug-Drug Interaction Prediction
Jane R. Kenny et al.
PHARMACEUTICAL RESEARCH (2012)
The Role of Therapeutic Drug Monitoring of Imatinib in Patients with Chronic MyeloidLeukemiaandMetastatic or Unresectable Gastrointestinal Stromal Tumors
Jennifer F. T. Teng et al.
THERAPEUTIC DRUG MONITORING (2012)
Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
Karel Eechoute et al.
CLINICAL CANCER RESEARCH (2011)
Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2
K. Eechoute et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Pharmacokinetic Impact of SLCO1A2 Polymorphisms on Imatinib Disposition in Patients With Chronic Myeloid Leukemia
Y. Yamakawa et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses
Johanna Honkalammi et al.
DRUG METABOLISM AND DISPOSITION (2011)
Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes
Noelia Nebot et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast
T. Karonen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia
N. Takahashi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe
Janne T. Backman et al.
DRUG METABOLISM AND DISPOSITION (2009)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Richard A. Larson et al.
BLOOD (2008)
Interaction of imatinib with human organic ion carriers
Shuiying Hu et al.
CLINICAL CANCER RESEARCH (2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
Annikka Kalliokoski et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib
Nielka R. van Erp et al.
CLINICAL CANCER RESEARCH (2007)
Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3
Johannes Noe et al.
DRUG METABOLISM AND DISPOSITION (2007)
Imatinib disposition and ABCB1 (MDR1, p-glycoprotein) genotype
H. Gurney et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Regional distribution of solute carrier mRNA expression along the human intestinal tract
Yvonne Meier et al.
DRUG METABOLISM AND DISPOSITION (2007)
Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans
R. Nakagomi-Hagihara et al.
XENOBIOTICA (2007)
Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1
R. Nakagomi-Hagihara et al.
XENOBIOTICA (2007)
Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide
M Niemi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics
Richard H. Ho et al.
GASTROENTEROLOGY (2006)
Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions
BW Ogilvie et al.
DRUG METABOLISM AND DISPOSITION (2006)
Metabolism and disposition of imatinib mesylate in healthy volunteers
HP Gschwind et al.
DRUG METABOLISM AND DISPOSITION (2005)
Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport
M Yamazaki et al.
XENOBIOTICA (2005)
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone
T Jaakkola et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects
JJ Lilja et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Clinical pharmacokinetics of imatinib
B Peng et al.
CLINICAL PHARMACOKINETICS (2005)
Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes
T Prueksaritanont et al.
PHARMACEUTICAL RESEARCH (2005)
Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
AE Bolton et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Effect of St John's wort on imatinib mesylate pharmacokinetics
RF Frye et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
C Dutreix et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia
O Kretz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
The influence of St. John's Wort on the pharmacokinetics and protein binding of imatinib mesylate
P Smith
PHARMACOTHERAPY (2004)
Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin:: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil
Y Shitara et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
DW Schneck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules
Z Nikolova et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone
M Niemi et al.
DIABETOLOGIA (2003)
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
C Kyrklund et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Gemfibrozil greatly increases plasma concentrations of cerivastatin
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
